Identification and Three-dimensional Structural Analysis of Nine Novel Mutations in Patients with Prothrombin Deficiency

Summary

Prothrombin deficiency is an autosomal recessive disorder associated with a moderately severe bleeding tendency. In this study, 13 patients with prothrombin deficiency were screened for the presence of alterations in the prothrombin gene, and nine novel candidate mutations were identified. Of 11 patients with hypoprothrombinemia, ten are homozygous for five mutations and one patient is a compound heterozygote. The two patients with dysprothrombinemia are homozygous for two mutations. Eight of nine mutations are missense ones associated with single amino acid substitutions in the propeptide (Arg-1Gln, Arg-2Trp), the kringle-1 (Asp118Try) and kringle-2 (Arg220Cys) domains and the catalytic serine protease domain (Gly330Ser, Ser354Arg, Arg382His and Arg538Cys). The ninth mutation is an in-frame deletion of 3 bp that results in the omission of one amino acid (del Lys 301/302). The combination of these missense mutations with crystal structures for α-thrombin and the prothrombin fragments 1 and 2 resulted in new insight into the function of α-thrombin. The hypoprothrombinemia mutations were inferred to affect either the cleavage of the propeptide from the Gla domain, the stability of the kringle-1 and −2 domains, or the close association of the A and B chains of the serine protease domain. The dysprothrombinemia mutations were inferred to directly affect catalytic function through their location at the active site crevice or exosite 1 within the serine protease domain.

Keywords

Prothrombin deficiency - dysprothrombinemia - hypoprothrombinemia - prothrombin

• References

• 1 Degen SJF, Davie EW. Nucleotide sequence of the gene for human prothrombin. Biochemistry 1987; 26: 6165-77.
• 2 Peyvandi F, Mannucci PM. Rare coagulation disorders. Thromb Haemost 1999; 82: 1207-14.
• 3 Sun WY, Witte DP, Degen JL, Colbert MC, Burkart MC, Holmback K, Xiao Q, Bugge TH, Degen SJF. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci USA 1998; 95: 7597-602.
• 4 Xue J, Wu Q, Westfield LA, Tuley EA, Lu D, Zhang Q, Shim K, Zheng X, Sadler JE. Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice. Proc Natl Acad Sci USA 1998; 95: 7603-7.
• 5 Henriksen RA, Mann KG. Identification of the primary structural defect in the dysthrombin thrombin Quick I: substitution of cystein for arginine-382. Biochemistry 1988; 27: 9160-5.
• 6 Henriksen RA, Mann KG. Substitution of valine for glycine-558 in the congenital dysthrombin thrombin Quick II alters primary substrate specificity. Biochemistry 1989; 28: 2078-82.
• 7 Iwahana H, Yoshimoto K, Shigekiyo T, Shirakami A, Saito S, Itakura M. Molecular and genetic analysis of a compound heterozygote for dysprothrombinemia of prothrombin Tokishima and hypoprothrombinemia. Am J Hum Gen 1992; 51: 1386-95.
• 8 Morishita E, Saito M, Kumabashiri I, Asakura H, Matsuda T, Yamaguchi K. Prothrombin Himi: a compound heterozygote for two dysfunctional prothrombin molecules (Met337→Thr and Arg338→His). Blood 1992; 80: 2275-80.
• 9 Poort SR, Michiels JJ, Reitsma PH, Bertina RM. Homozygosity for a novel mutation in the prothrombin gene causing a severe bleeding disorder. Thromb Haemost 1994; 72: 819-24.
• 10 James HL, Kim DJ, Zheng DQ, Girolami A. Prothrombin Padua I: incomplete activation due to an amino acid substitution at a factor Xa cleavage site. Blood Coag Fibrinol 1994; 05: 841-4.
• 11 James HL, Kim DJ, Zheng DQ, Girolami A. Prothrombin Molise I: documentation of a second incidence of a critical Arg near the active site. Thromb Res 1995; 80: 363-6.
• 12 Miyata T, Zheng YZ, Kato A, Kato H. A point mutation (Arg271→Cys) of a homozygote for dysfunctional prothrombin, prothrombin Obihiro, which has a region of high sequence variability. Br J Haemat 1995; 90: 688-92.
• 13 Degen SJF, McDowell SA, Sparks LM, Scharrer I. Prothrombin Frankfurt: a dysfunctional prothrombin characterized by substitution of Glu-466 by Ala. Thromb Haemost 1995; 73: 203-9.
• 14 O’Marcaigh AS, Nichols WL, Hassinger NL, Mullins JD, Mallouh AA, Gilchrist GS, Owen WG. Genetic analysis and functional characterization of prothrombins Corpus Christi (Arg382→Cys), Daharan (Arg271→His) and hypoprothrombinemia. Blood 1996; 88: 2611-18.
• 15 Poort SR, Landolfi R, Bertina RM. Compound heterozygosity for two novel missense mutations in the prothrombin gene in a patient with a severe bleeding tendency. Thromb Haemost 1997; 77: 610-15.
• 16 Tamary H, Surrey S, Augustine J, Shalmon L, Schwartz E, Rappaport EF. Molecular analysis of a compound heterozygote for hypoprothrombinemia and dysprothrombinemia (-G 7248/7249 and Arg 340 Trp). Blood Coag Fibrinol 1997; 08: 337-43.
• 17 Henriksen RA, Dunham CK, Miller LD, Casey TJ, Menke JB, Knupp CL, Usala SJ. Prothrombin Greenville, Arg517→Gln, identified in an individual heterozygous for dysprothrombinemia. Blood 1998; 91: 2026-31.
• 18 Akhavan S, Rocha E, Zeinali S, Mannucci PM. Gly319→Arg substitution in the dysfunctional prothrombin Segovia. Br J Haemat 1999; 105: 667-9.
• 19 Lak M, Sharifian R, Peyvandi F, Mannucci PM. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haemat 1998; 103: 1067-9.
• 20 Bertina RM, van der Marel-van WNieuwkoop, Loeliger EA. Spectrophotometric assays of prothrombin in plasma of patients using oral anticoagulants. Thromb Haemost 1979; 42: 1296-1305.
• 21 Denson KWE, Barret R, Biggs R. The specific thrombin assay using the Taipan snake venom. Br J Haematol 1971; 21: 219-26.
• 22 Park CH, Tulinsky A. Three-dimensional structure of the kringle sequence: structure of prothrombin fragment 1. Biochemistry 1986; 25: 3977-82.
• 23 Soriano-Garcia M, Park CH, Tulinsky A, Ravichandran KG, Skrzypczak E. Structure of Ca²⁺ prothrombin fragment 1 including the conformation of the Gla domain. Biochemistry 1989; 28: 6805-10.
• 24 Arni RK, Padmanabhan K, Padmanabhan KP, Wu TP, Tulinsky A. Structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human PPACK-thrombin. Biochemistry 1993; 32: 4727-37.
• 25 Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hossteenge J. The refined 1.9 Å crystal structure of human α-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 1989; 08: 3467-75.
• 26 Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 1983; 22: 2577-637.
• 27 Lee B, Richards FM. The interpretation of protein structures: estimation of static accessibility. J Mol Biol 1971; 55: 379-400.
• 28 Sali A, Blundell TL. The definition of topological equivalence in homologous and analogous structures: a procedure involving a comparison of local properties and relationships. J Mol Biol 1990; 212: 403-28.
• 29 Pan LC, Price PA. The propeptide of rat bone gamma-carboxyglutamic acid protein shares homology with other vitamin K-dependent protein precursors. Proc Natl Acad Sci USA 1985; 82: 6109-13.
• 30 Chu K, Wu SM, Stanley T, Stafford DW, High KA. A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 1996; 98: 1619-25.
• 31 Sanford DG, Kanagy C, Sudmeier JL, Furie BC, Furie B, Bachovchin WW. Structure of the propeptide of prothrombin containing the gamma-carboxylation recognition site determined by two-dimensional NMR spectroscopy. Biochemistry 1991; 30: 9835-41.
• 32 Handford PA, Winship PR, Brownlee GG. Protein engineering of the propeptide of human factor IX. Protein Eng 1991; 04: 319-23.
• 33 Diuguid DL, Rabiet MJ, Furie BC, Laibman HA, Furie B. Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor. Proc Natl Acad Sci USA 1986; 83: 5803-7.
• 34 Ware J, Diuguid DL, Leibman HA, Rabiet MJ, Kasper CK, Furie BC, Furie B, Stafford DW. Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties. J Biol Chem 1989; 264: 11401-6.
• 35 Gandrille S, Alhenc-Gelas M, Gaussem P, Aillaud MF, Dupuy E, Juhan-Vague I, Aiach M. Five novel mutations located in exons III and IX of the protein C gene in patients presenting with defective protein C anticoagulant activity. Blood 1993; 82: 159-68.
• 36 Bristol JA, Ratcliffe JV, Roth DA, Jacobs MA, Furie BC, Furie B. Biosynthesis of prothrombin: intracellular localization of the vitamin K-dependent carboxylase and the sites of γ-carboxylation. Blood 1996; 88: 2585-93.
• 37 Huber P, Schmitz T, Griffin J, Jacobs M, Walsh C, Furie B, Furie BC. Identification of amino acids in the γ-carboxylation recognition site on the propeptide of prothrombin. J Biol Chem 1990; 265: 12467-73.
• 38 Soriano-Garcia M, Padmanabhan K, de Vos AM, Tulinsky A. The Ca²⁺ ion and menbrane binding structure of the Gla domain of Ca-prothrombin fragment 1. Biochemistry 1992; 31: 2554-66.
• 39 Bristol JA, Furie BC, Furie B. Propeptide processing during factor IX biosynthesis. Effect of point mutations adjacent to the propeptide cleavage site. J Biol Chem 1993; 268: 7577-84.
• 40 Lind B, Johnsen AH, Thorsen S. Naturally occurring Arg-1 to His mutation in human protein C leads to aberrant propeptide processing and secretion of dysfunctional protein C. Blood 1997; 89: 2807-16.
• 41 Wojcik EGC, Van Den Berg M, Poort SR, Bertina RM. Modification of the N-terminus of human factor IX by defective propeptide cleavage or acetylation results in a destabilized calcium-induced conformation: effects on phospholipid binding and activation by factor XIa. Biochemistry 1997; 323: 629-36.
• 42 Jackson CM. Physiology and biochemistry of prothrombin. Haemostasis and Thrombosis, Vol 1. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. Churchill Livingstone. 3rd edition. 1994: 397-438.
• 43 Giannelli F, Green PM, High KA, Sommer S, Poon MC, Ludwig M, Schwaab R, Reitsma PH, Goossens M, Yoshioka A, Brownlee GG. Haemophilia B: a database of point mutations and short additions and deletions – fourth edition. Nucl Acid Res 1993; 21: 3075-87.
• 44 Bode W, Turk D, Karshikov A. The refined 1.9 Å X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human α-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Science 1992; 01: 426-71.
• 45 Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 1982; 257: 7944-7.
• 46 Hofsteenge J, Taguchi H, Stone SR. Effect of thrombomodulin on the kinetics of the interaction of thrombin with substrates and inhibitors. Biochem J 1986; 237: 243-51.
• 47 Jakubowski HV, Kline MD, Owen WG. The effect of bovine thrombomodulin on the specificity of bovine thrombin. J Biol Chem 1986; 261: 3876-82.
• 48 Hofsteenge J, Stone SR. The effect of thrombomodulin on the cleavage of fibrinogen and fibrinogen fragments by thrombin. Eur J Bioch 1987; 167: 49-56.
• 49 Tsiang M, Lentz SR, Dittman WA, Wen D, Scarpati EM, Sadler JE. Equilibrium binding of thrombin to recombinant human thrombomodulin: effect of hirudin, fibrinogen, factor Va and peptide analogues. Biochemistry 1990; 29: 10602-12.
• 50 Grütter MG, Priestle JP, Rahuel J, Brossenbacher H, Bode W, Hofsteenge J, Stone SR. Crystal structure of the thrombin-hirudin complex: A novel mode of serine protease inhibition. EMBO J 1990; 08: 2361-5.
• 51 Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton II JW. The structure of a complex of recombinant hirudin and human α-thrombin. Science 1990; 249: 277-80.
• 52 Rogers SJ, Pratt CW, Whinna HC, Church FC. Role of thrombin exosites in inhibition by heparin cofactor II. J Biol Chem 1992; 267: 3613-7.
• 53 Sun WY, Burkart MC, Holahan JR, Degen SDF. Prothrombin San Antonio: a single amino acid substitution at a Factor Xa activation site (Arg320 to His) results in dysprothrombinemia. Blood 2000; 95: 711-4.
• 54 Lefkowitz JB, Haver T, Clarke S, Jaconson L, Weller A, Nuss R, Manco-Johnson M, Hathaway WE. The prothrombin Denver patient has two different prothrombin point mutations resulting in Glu300Lys and Glu309Lys substitutions. Br J Haemat 2000; 108: 182-7.